Cancer Organoid

Gastric Cancer Organoid

Gastric cancer organoids are three-dimensional (3D) models that closely replicate the structure and cellular composition of actual tumor tissue.
By preserving key characteristics of gastric cancer, including genetic mutations and protein expression patterns, these organoids serve as reliable models for cancer research.
Their ability to maintain tumor heterogeneity and accurately mimic the tumor microenvironment (TME) makes them invaluable for studying disease progression and treatment responses.In particular, organoids derived from the ascitic fluid of patients with advanced gastric cancer reflect the characteristics of metastatic tumors and treatment resistance, playing an important role in evaluating responses to standard therapies and in the development of novel treatment strategies.
As physiologically relevant models, these cancer organoids closely mimic the pathological and molecular features of gastric cancer, making them essential tools for studying disease progression, evaluating drug responses, and driving the development of precision medicine-based cancer therapies.


Price	1784€+ Login to see price
Organism	Human
Product Type	Tissue derived organoid
Tissue	Stomach (Gastric)
Disease	Gastric Cancer, Malignant ascites

Applications

Toxicity

Small molecules

mRNA

Antibody

Cancer vaccine

Immune Cells

Immuno Oncology with TME

Cytotoxic T cell

TIL (Tumor infiltrating lymphocytes)

Regulatory T cell

Macrophage

CAF (Cancer associate fibroblast)

Description

Cellular and structural similarity

Our gastric cancer organoids exhibit a high degree of pathological similarity to patient-derived tumor tissues, expressing key gastric cancer markers such as CK7, CEA, and LGR5. Immunohistochemistry (IHC) analyses confirm that these markers are expressed in the organoids in patterns consistent with those observed in primary tumors, accurately reflecting the differentiation status and histological characteristics of the original tissue.

These pathological marker analyses demonstrate that gastric cancer organoids faithfully recapitulate the morphological and molecular features of patient tumors, establishing them as a reliable platform for cancer pathology research, drug development, and the evaluation of personalized therapeutic strategies.

Cellular and structural similarity

Drug sensitivity testing for Precision Oncology

A tailored solution for evaluating the efficacy and resistance of new drugs is available using an established gastric cancer (GC) organoid library.

By leveraging comprehensive drug sensitivity data, the most suitable organoid lines are selected based on the characteristics of the investigational drug, enabling precise and reliable drug testing.

Drug sensitivity tests have been conducted using Carboplatin and Cisplatin, Paclitaxel which are widely used in clinical gastric cancer treatment, and drug response data has been collected from a subset of gastric cancer organoid models, comprising over 16 distinct lines.

This dataset continues to expand as additional testing is performed.

This organoid-based drug sensitivity testing platform enhances the efficiency and reliability of the drug development process and contributes to the advancement of personalized cancer treatment strategies.